Hironori Yoshida

Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease

Osamu Kanai, Young Hak Kim, Yoshiki Demura et al. · Thoracic Cancer · 2018 · 140 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients

Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji et al. · Scientific Reports · 2017 · 119 citations · Full text

Medicine, Genetics, Oncology +17

Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy

Kohei Fujita, Young Hak Kim, Osamu Kanai et al. · Respiratory Medicine · 2018 · 109 citations

Medicine, Infectious Diseases, Oncology +15

Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy

Ryusuke Hatae, Kenji Chamoto, Young Hak Kim et al. · JCI Insight · 2019 · 90 citations · Full text

Medicine, Immunology, Oncology +17

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation

Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki et al. · Nature Communications · 2020 · 83 citations · Full text

Medicine, Oncology, Pharmacology +17